Important Update on Cediranib development for Alveolar Soft Part Sarcoma (ASPS)

Dear ASPS community. Many of our patients who participated in Cediranib clinical trials reported on our FORUM positive ASPS response to the drug. The conclusion that Cediranib shows favorable activity in ASPS is detailed in a summary of a Phase 2 clinical trial by Dr. Kummar in the 2011 meeting of the American Society of Clinical Oncology (ASCO). According to this study that included 36 ASPS patients, “Cediranib has substantial single-agent activity in ASPS, with a > 40% response rate and a disease control rate of 78%”. Those are very exciting news for us as so far no other drug showed efficacy in ASPS.

However, recently we learned that AstraZeneca, the developer of Cediranib has decided to transfer the development of Cediranib to the National Cancer Institute (NCI). AstraZeneca transferred 100 kg of Cediranib to the NCI for that purpose and the NCI opened a new Phase 2 clinical trial for ASPS patients. The goal of the new NCI trial is to confirm the early Phase 2 results and to compare Cediranib to Sunitinib, another drug that was tested on 9 ASPS patients at the Istituto Nazionale Tumori, Milan, Italy. The Sunitinib study showed partial response in 5 of the 9 ASPS patients.

The good news are that there is a possibility that one of the drugs will be selected and then be available for ASPS patients.

The new Cediranib and Sunitinib Phase 2 clinical trial is now open in California: Santa Monica Oncology Center, Maryland: NIH/NCI Bethesda, Massachusetts: Dana Farber and Texas: MD Anderson.

The NCI is making efforts to make sure that the study will be conclusive. Therefore travel and additional support will be given to every ASPS patient who participates in the trial in the NCI. The NCI will accept and pay travel also for ASPS patients who are not US residents. NonUS residents need to arrive to any US port and then their flight to the NCI, their treatment and minimal stay will be paid by the NCI!

For full details please click and read the details in the following link: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma. For more information, contact the NCI Referral Office at 1-888-NCI-1937, the study number is: NCT01391962.

We hope that the study will be conclusive and finally the first effective therapy for ASPS will be validated and then be available for all ASPS patients.

Best Wishes,
Yosef Landesman
______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail: landesmany@yahoo.com